View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
Guy Sips
  • Guy Sips

Jensen-Group All-time high FY24 revenues forms a strong basis for FY25

In FY24, Jensen-Group achieved remarkable milestones, establishing new standards in both operational and financial performance. We maintain our Accumulate rating and have slightly increased our Target Price from €50 to €51.5, in line with our updated DCF, as we believe Jensen-Group can continue its consistent growth trajectory.

 PRESS RELEASE

argenx Highlights FcRn Leadership with Long-term Data and Transformati...

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve rapid, substantial, and sustained efficacy across multiple dosing regimens, supporting individualized treatment approachADHERE+ oral presentation builds upon evidence of VYVGART Hytrulo driving improved functional ability in CIDP Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Eurone...

Aaron Brodjanac ... (+7)
  • Aaron Brodjanac
  • Baptiste Salaville
  • Chaima Ferrandon
  • Charlotte Vaisse
  • Marc Lavaud
  • Sven Edelfelt
  • Thomas Zlowodzki
Aaron Brodjanac ... (+7)
  • Aaron Brodjanac
  • Baptiste Salaville
  • Chaima Ferrandon
  • Charlotte Vaisse
  • Marc Lavaud
  • Sven Edelfelt
  • Thomas Zlowodzki
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Morning Notes : AALB NA, AGS BB, ARGX BB, CFEB BB, CRBN NA, CMBT BB, M...

: AALB NA, AGS BB, ARGX BB, CFEB BB, CRBN NA, CMBT BB, MDXH BB, PNL NA, UCB BB, VAN BB, WDP BB, CTPNV NA, SYENS BB

Thomas Vranken
  • Thomas Vranken

argenx FIRST LOOK: FY24 results highlight transition to sustainable pr...

argenx reported its FY24 financial results, underscoring Vyvgart's sustained commercial momentum and the company's pivot toward sustainable profitability. Despite increasing competition, we see no signs of stopping. For 2025, we mainly look forward to Vyvgart's ramp-up in CIDP, its PFS approval (PDUFA April 10), a PoC readout in LN and ARGX-119's first clinical results in CMS. We maintain our € 670 TP and Accumulate rating.

 PRESS RELEASE

argenx Reports Full Year 2024 Financial Results and Provides Fourth Qu...

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update $737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET...

 PRESS RELEASE

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Present at TD Cowen 45th Annual Healthcare Conference February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx websi...

 PRESS RELEASE

argenx to Report Full Year 2024 Financial Results and Fourth Quarter B...

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of th...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart

Lotus Bakeries/Attractive entry point on unwarranted de-rating/BUY (pr...

We upgrade Lotus Bakeries from Hold to BUY, as we remain convinced by this Belgian gem's unique self-funded organic growth story in the Snacking segment, as demonstrated by its double-digit top and bottom line CAGR over 2024-30F. Management has a strong track record in executing its strategy, allowing Lotus Bakeries organic sales growth to be 4x higher than the industry average over 2016-24. 2024 was an exceptional year for the group, with its organic sales growth being 12x superior to the one o...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ArcelorMittal: 4Q24 EBITDA beats by 8%, strong year-end CF, dividend +10%. Ayvens: Still in neutral. BAM: Preview - non-res UK and possible share buyback. IBA: Signs first P1 system order in the South Asian region with AIG in Hyderabad, India. Kinepolis: Reasonable start to 2025 for US/Canada and France box office, attendance. Lotus Bakeries: Another strong year for Biscoff. Ontex: Post Christmas Turkey

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Lewi
Guy Sips
  • Guy Sips

Lotus Bakeries FIRST LOOK – FY24 Results : Bake Baby Bake

In 2024, Lotus Bakeries achieved significant double-digit growth of almost 15.9% (KBCSe 17.2%) to € 1,232m (KBCSe 1,245.8 million). Lotus Bakeries indicated that the organic growth in FY24 is driven almost exclusively by record volume growth. Price increases have, combined with FX impact, a limited contribution of less than 2% The significant volume increase in 2024 demonstrates continued momentum and robust demand across the entire product range and across the different geographies. All thre...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Elia: Postponement of Elisabeth Island. Exor: Racy, red, and impressive FY24 results. Lotus Bakeries: Mondelez 4Q24 results. Melexis: 4Q24 results – bigger inventory correction. UCB: Evenity reaches US$1.5bn sales in FY24

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN AMRO: ARES Infrastructure deal helps CET1 ratio ahead of possible add-ons in 1Q25. Ackermans & van Haaren: +50% in five years the growth target for Bank Van Breda. Lotus Bakeries: FY24 preview - another year of strong execution. Staffing: Belgium December Temp volume trend stable at -3.4% YoY on tougher comps. Staffing: Manpower: 1Q25 outlook missed

Argen X SE: 1 director

A director at Argen X SE sold 9,950 shares at 624.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Stephane Houri
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch